Effect of a One Time Dose of Cholecalciferol on Serum Concentration of 25-Hydroxyvitamin D and Macrophages
NCT ID: NCT02920502
Last Updated: 2016-10-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Total Enrollment
24 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-06-30
Study Completion Date
2015-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Optimal Vitamin D dosing to obtain adequate serum concentrations of 25-hydroxyvitamin D (25OHD) is controversial. The optimal dose and dosing interval is unknown, and the tendency over the last few years is to give higher, less frequent doses. Disease-specific dosing is of interest, and there may be optimal serum concentration targets based on disease process. The best evidence so far is for optimal bone health, where most experts agree that 25OHD serum concentration should be above 30 ng/ml.
There is mounting evidence that Vitamin D therapy will reduce inflammatory response and macrophage activation. The optimal dosing needed to decrease the inflammatory response is unclear, although our recent mouse model has demonstrated that a onetime high dose is effective. The investigators therefore hypothesize that a one-time high dose of cholecalciferol will be effective in suppression of macrophage production of tumor necrosis factor-alpha (TNFa) and inducible nitric oxide synthase (iNOS). The purpose of this pilot study is to assess the optimum dosage for the most macrophage suppression.
There is mounting evidence that Vitamin D therapy will reduce inflammatory response and macrophage activation. The optimal dosing needed to decrease the inflammatory response is unclear, although our recent mouse model has demonstrated that a onetime high dose is effective. The investigators therefore hypothesize that a one-time high dose of cholecalciferol will be effective in suppression of macrophage production of tumor necrosis factor-alpha (TNFa) and inducible nitric oxide synthase (iNOS). The purpose of this pilot study is to assess the optimum dosage for the most macrophage suppression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Pharmacokinetic Study of Daily Versus Monthly High-Dose Cholecalciferol Supplementation
NCT01079923
Healthy Volunteers
COMPLETED
NA
Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function
NCT02091219
Vitamin D Deficiency
COMPLETED
EARLY_PHASE1
Vitamin D Raising and Maintaining Blood Serum 25(OH)D3 Levels
NCT03099759
Vitamin D Deficiency
COMPLETED
NA
Cholecalciferol Supplementation Effect on Parathyroid Hormone in Hemodialysis Patients
NCT03648528
Vitamin D Deficiency
Hemodialysis Patient
COMPLETED
PHASE4
Effect of Vitamin D Oral Supplements on 25 OH Vitamin D Levels
NCT01170494
Vitamin D Deficiency
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
3.4.1 Study Medication (Vitamin D/Placebo): Patients will be blocked randomized into one of four groups using a balanced assignment. The target number of patients is 20, with five patients who have successfully completed all assessments in each group. Groups will be closed to enrollment once their target is reached. The recruitment will continue until every group has reached its target. The investigative pharmacy will prepare each dosage according to the randomization and will hold the key to the dosing.
Participants and investigators will be blinded to those receiving cholecalciferol which comes in 50,000 I.U. dose capsules and those receiving a placebo. Participants will be randomized to 1 of 4 doses as outlined below. All participants will receive the same number of capsules. Five participants will be in each group and will be dosed according to the following dosing schema:
Table 1: Dosing Schema
Cholecalciferol Dosage Group
Control: 0 Cholecalciferol Capsules 4 Placebo Capsules
50,000 I.U.: 1 Cholecalciferol Capsules 3 Placebo Capsules
100,000 I.U.: 2 Cholecalciferol Capsules 2 Placebo Capsules
200,000 I.U.: 4 Cholecalciferol Capsules 0 Placebo Capsules
3.4.2. Skin Thickness Measurement:All testing sites will be evaluated for redness. Skin thickness will also be measured using a micrometer before and after UV exposure.
3.4.3. MED/Sunburn Test: This procedure involves exposing eight 6mm areas of skin over increasing doses of simulated solar radiation (SSR), while the rest of the body is draped. SSR is delivered by a 1,000-Watt xenon arc lamp, which emits ultraviolet wavelengths from 290-400 nm, closely resembling natural sunlight. The minimal erythema dose (MED) will be determined approximately 24 hours after initial exposure by using a chromameter that records the values of redness associated with each exposed 1cm area. The overall differences in MED between the subjects will be assessed.
3.4.4. UVR Exposure: This procedure involves exposing four 6mm areas of skin over increasing doses of simulated solar radiation (SSR), while the rest of the body is draped. SSR is delivered by a 1,000-Watt xenon arc lamp, which emits ultraviolet wavelengths from 290-400 nm, closely resembling natural sunlight. The sites to be exposed will be dosed as follows: 1 MED, 2 MED, 3 MED, 3 MED. Two sites will be exposed for this study, one before study medication dosing and one after study medication dosing.
3.4.5. Blood Draw: samples will be taken by venipuncture to provide samples for analysis of serum 25OHD and macrophages.
* Serum 25OHD and 1,25(OH): Up to 6ml blood will be drawn to measure 25OHD and sent to Heartland Assays, LLC.
* Banked Serum:Up to 30ml of blood serum will be collected and stored in the Dermatology research lab and will then be analyzed with the Macrophage Harvest.
* Macrophage Harvest: One-time collection up to 180ml whole blood will be processed and purified to isolate peripheral blood macrophages in the Dermatology research lab.
3.4.6. Punch Biopsy (Tissue Sample): A punch biopsy is the removal of a small (pencil eraser-sized) circle of skin using a cookie cutter-like instrument. This procedure involves numbing the designated area of skin with lidocaine and the removal of a circle of skin. Prior to obtaining the punch biopsy, the skin will be injected with lidocaine, a painkiller similar to that used by dentists. Although the lidocaine can tingle or hurt briefly during the numbing process, volunteers should not feel any pain while the punch biopsy is being obtained. The circle is then closed using one to five fine stitches per site, which prevents bleeding, speeds healing, and improves the appearance. The stitches are removed 10-14 days later.
3.4.7. Photographs: Photographs of the testing sites will be taken through-out this protocol. In the event that a photograph is taken of the subject's face or any other identifiable feature, the subject's identity may become known.
3.5. STUDY VISITS
3.5.1 Screening Visit
* Informed Consent
* Inclusion and Exclusion Criteria
* Medical \& Dermatological History
* Physical Examination and Vital Signs of Concomitant Medications/Procedures
* Blood Draw: baseline serum vitamin D levels and banked serum
* Photographs of testing sites of MED testing
3.5.2 Visit 2: UVR #1
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Site #1 UVR Exposure: 1, 2, 3, and 3 MED
3.5.3 Visit 3: 24hours post UVR #1
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures
* Chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
3.5.4 Visit 4: 48 hours post UVR #1
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Punch Biopsy of one 3 MED from site #I
3.5.5 Visit 5: 72 hours post UVR #1
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
3.5.6 Visit 6:1week post UVR #1
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
3.5.7 Visit 7: UVR #2: 2 weeks post UVR #1
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of Photographs of testing sites
* Skin Thickness Measurements
* Site #2 UVR Exposure: I, 2, 3, and 3 MED
* One-time dose of study medication (vitamin D or placebo), 1 hour after UVR
3.5.8 Visit 8: 24 hours post UVR #2
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of Chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.9 Visit 9: 48 hours post UVR #2
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
* Punch Biopsy of one 3 MED from site #2
3.5.10 Visit 10: 72 hours post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures
* Chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.11 Visit 11: 1 week post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.12 Visit 12: 2 weeks post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.13 Visit 13: One month post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures
* Photographs of testing sites
4\. RISKS AND DISCOMFORTS - MINIMIZED
4.1. Study Medication (Vitamin D/Placebo): Vitamin D is well tolerated and often used in clinical practice. It is freely available as an over the counter supplement. There are few side effects to oral vitamin D, with the most severe being hypercalcemia with prolonged use of a high dose. Vitamin D toxicity can occur when the active form is given (1,25 dihydroxyvitamin D) or with prolonged exposure to high dose vitamin D3. Both young and old adults have taken one time high dose vitamin D3 safely. It is possible that an allergic reaction could occur to the medication and participants will be asked to report and symptoms.
4.2. Skin Thickness Measurement: there are no known risks to evaluating or measuring the skin's thickness with a micrometer.
4.3. Minimal Erythema Dose (MED) and Ultraviolet Light Exposure (UVR): The risks associated with this procedure are minimal, as only the testing sites will be exposed. The consequences of being exposed to UV light are short-term, and primarily involve mild redness at the exposure site followed by minor itching and dryness of the skin several days later. The degree of the sunburn is typically mild to moderate and the UV dose used is not enough to cause blistering of the skin.
4.4. Blood Draw: Risks from a blood draw may include the occurrence of discomfort and/or bruise at the site of puncture and, less likely, the formation of a small clot, swelling of the vein, or bleeding from the puncture site.
4.5. Punch Biopsy (Tissue Sample): Punch biopsies pose minimal risk, and volunteers are instructed as to the proper care of the biopsy site. Lidocaine may cause a tingling or burning sensation when injected into the skin. Potential problems localized to the biopsy site include bleeding or oozing, discomfort, or infection. The biopsy site will heal with a small, flat scar, which may be red for several months. The scar may also turn lighter or darker than the surrounding skin after some time.
4.6. Photographs: There are no known risks to taking photographs. In the event a photograph is taken of the subject's face or any other identifying feature, the patient's identity may be known.
Participants and investigators will be blinded to those receiving cholecalciferol which comes in 50,000 I.U. dose capsules and those receiving a placebo. Participants will be randomized to 1 of 4 doses as outlined below. All participants will receive the same number of capsules. Five participants will be in each group and will be dosed according to the following dosing schema:
Table 1: Dosing Schema
Cholecalciferol Dosage Group
Control: 0 Cholecalciferol Capsules 4 Placebo Capsules
50,000 I.U.: 1 Cholecalciferol Capsules 3 Placebo Capsules
100,000 I.U.: 2 Cholecalciferol Capsules 2 Placebo Capsules
200,000 I.U.: 4 Cholecalciferol Capsules 0 Placebo Capsules
3.4.2. Skin Thickness Measurement:All testing sites will be evaluated for redness. Skin thickness will also be measured using a micrometer before and after UV exposure.
3.4.3. MED/Sunburn Test: This procedure involves exposing eight 6mm areas of skin over increasing doses of simulated solar radiation (SSR), while the rest of the body is draped. SSR is delivered by a 1,000-Watt xenon arc lamp, which emits ultraviolet wavelengths from 290-400 nm, closely resembling natural sunlight. The minimal erythema dose (MED) will be determined approximately 24 hours after initial exposure by using a chromameter that records the values of redness associated with each exposed 1cm area. The overall differences in MED between the subjects will be assessed.
3.4.4. UVR Exposure: This procedure involves exposing four 6mm areas of skin over increasing doses of simulated solar radiation (SSR), while the rest of the body is draped. SSR is delivered by a 1,000-Watt xenon arc lamp, which emits ultraviolet wavelengths from 290-400 nm, closely resembling natural sunlight. The sites to be exposed will be dosed as follows: 1 MED, 2 MED, 3 MED, 3 MED. Two sites will be exposed for this study, one before study medication dosing and one after study medication dosing.
3.4.5. Blood Draw: samples will be taken by venipuncture to provide samples for analysis of serum 25OHD and macrophages.
* Serum 25OHD and 1,25(OH): Up to 6ml blood will be drawn to measure 25OHD and sent to Heartland Assays, LLC.
* Banked Serum:Up to 30ml of blood serum will be collected and stored in the Dermatology research lab and will then be analyzed with the Macrophage Harvest.
* Macrophage Harvest: One-time collection up to 180ml whole blood will be processed and purified to isolate peripheral blood macrophages in the Dermatology research lab.
3.4.6. Punch Biopsy (Tissue Sample): A punch biopsy is the removal of a small (pencil eraser-sized) circle of skin using a cookie cutter-like instrument. This procedure involves numbing the designated area of skin with lidocaine and the removal of a circle of skin. Prior to obtaining the punch biopsy, the skin will be injected with lidocaine, a painkiller similar to that used by dentists. Although the lidocaine can tingle or hurt briefly during the numbing process, volunteers should not feel any pain while the punch biopsy is being obtained. The circle is then closed using one to five fine stitches per site, which prevents bleeding, speeds healing, and improves the appearance. The stitches are removed 10-14 days later.
3.4.7. Photographs: Photographs of the testing sites will be taken through-out this protocol. In the event that a photograph is taken of the subject's face or any other identifiable feature, the subject's identity may become known.
3.5. STUDY VISITS
3.5.1 Screening Visit
* Informed Consent
* Inclusion and Exclusion Criteria
* Medical \& Dermatological History
* Physical Examination and Vital Signs of Concomitant Medications/Procedures
* Blood Draw: baseline serum vitamin D levels and banked serum
* Photographs of testing sites of MED testing
3.5.2 Visit 2: UVR #1
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Site #1 UVR Exposure: 1, 2, 3, and 3 MED
3.5.3 Visit 3: 24hours post UVR #1
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures
* Chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
3.5.4 Visit 4: 48 hours post UVR #1
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Punch Biopsy of one 3 MED from site #I
3.5.5 Visit 5: 72 hours post UVR #1
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
3.5.6 Visit 6:1week post UVR #1
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
3.5.7 Visit 7: UVR #2: 2 weeks post UVR #1
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of Photographs of testing sites
* Skin Thickness Measurements
* Site #2 UVR Exposure: I, 2, 3, and 3 MED
* One-time dose of study medication (vitamin D or placebo), 1 hour after UVR
3.5.8 Visit 8: 24 hours post UVR #2
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of Chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.9 Visit 9: 48 hours post UVR #2
* Review of lnclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
* Punch Biopsy of one 3 MED from site #2
3.5.10 Visit 10: 72 hours post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures
* Chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.11 Visit 11: 1 week post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.12 Visit 12: 2 weeks post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures of chromameter reading
* Photographs of testing sites
* Skin Thickness Measurements
* Blood Draw: Serum vitamin D levels and banked serum
3.5.13 Visit 13: One month post UVR #2
* Review of Inclusion and Exclusion Criteria
* Review of Adverse Events \& Concomitant Medications/Procedures
* Photographs of testing sites
4\. RISKS AND DISCOMFORTS - MINIMIZED
4.1. Study Medication (Vitamin D/Placebo): Vitamin D is well tolerated and often used in clinical practice. It is freely available as an over the counter supplement. There are few side effects to oral vitamin D, with the most severe being hypercalcemia with prolonged use of a high dose. Vitamin D toxicity can occur when the active form is given (1,25 dihydroxyvitamin D) or with prolonged exposure to high dose vitamin D3. Both young and old adults have taken one time high dose vitamin D3 safely. It is possible that an allergic reaction could occur to the medication and participants will be asked to report and symptoms.
4.2. Skin Thickness Measurement: there are no known risks to evaluating or measuring the skin's thickness with a micrometer.
4.3. Minimal Erythema Dose (MED) and Ultraviolet Light Exposure (UVR): The risks associated with this procedure are minimal, as only the testing sites will be exposed. The consequences of being exposed to UV light are short-term, and primarily involve mild redness at the exposure site followed by minor itching and dryness of the skin several days later. The degree of the sunburn is typically mild to moderate and the UV dose used is not enough to cause blistering of the skin.
4.4. Blood Draw: Risks from a blood draw may include the occurrence of discomfort and/or bruise at the site of puncture and, less likely, the formation of a small clot, swelling of the vein, or bleeding from the puncture site.
4.5. Punch Biopsy (Tissue Sample): Punch biopsies pose minimal risk, and volunteers are instructed as to the proper care of the biopsy site. Lidocaine may cause a tingling or burning sensation when injected into the skin. Potential problems localized to the biopsy site include bleeding or oozing, discomfort, or infection. The biopsy site will heal with a small, flat scar, which may be red for several months. The scar may also turn lighter or darker than the surrounding skin after some time.
4.6. Photographs: There are no known risks to taking photographs. In the event a photograph is taken of the subject's face or any other identifying feature, the patient's identity may be known.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammation
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1: Placebo
Normal Healthy Volunteers without any skin pathology, will receive placebo
Group Type
PLACEBO_COMPARATOR
Arm 1: Placebo
Intervention Type
OTHER
One time dose of Placebo
Arm 2: cholecalciferol: 50,000 IU
Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
Group Type
EXPERIMENTAL
Arm 2: cholecalciferol 50,000 IU
Intervention Type
DIETARY_SUPPLEMENT
One time dose of cholecalciferol 50,000 IU
Arm 3: cholecalciferol: 100,000 IU
Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
Group Type
EXPERIMENTAL
Arm 3: cholecalciferol 100,000 IU
Intervention Type
DIETARY_SUPPLEMENT
One time dose of cholecalciferol 100,000 IU
Arm 4: cholecalciferol: 200,000 IU
Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
Group Type
EXPERIMENTAL
Arm 4: cholecalciferol 200,000 IU
Intervention Type
DIETARY_SUPPLEMENT
One time dose of cholecalciferol 200,000 IU
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Arm 2: cholecalciferol 50,000 IU
One time dose of cholecalciferol 50,000 IU
Intervention Type
DIETARY_SUPPLEMENT
Arm 3: cholecalciferol 100,000 IU
One time dose of cholecalciferol 100,000 IU
Intervention Type
DIETARY_SUPPLEMENT
Arm 4: cholecalciferol 200,000 IU
One time dose of cholecalciferol 200,000 IU
Intervention Type
DIETARY_SUPPLEMENT
Arm 1: Placebo
One time dose of Placebo
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults ages 18 years or older
* Fitzpatrick Skin Type I-Ill
* In good general health and able to list all current medications and medical conditions
* Capable of giving informed consent
* Fitzpatrick Skin Type I-Ill
* In good general health and able to list all current medications and medical conditions
* Capable of giving informed consent
Exclusion Criteria
* Volunteers ages 18 years or younger
* Women who are pregnant, nursing, or who may become pregnant in the next 3 months
* Participants taking illegal drugs
* Chronic medical conditions
* Currently taking statins, ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil
* Currently consuming 800 IU or more of vitamin D a day
* Current or recent use of anti-inflammatory medications or any other medications that may cause photosensitivity, at the discretion of the Pl.
* Women who are pregnant, nursing, or who may become pregnant in the next 3 months
* Participants taking illegal drugs
* Chronic medical conditions
* Currently taking statins, ketoconazole, colestipol, cholestyramine, phenobarbitol, phenytoin, or mineral oil
* Currently consuming 800 IU or more of vitamin D a day
* Current or recent use of anti-inflammatory medications or any other medications that may cause photosensitivity, at the discretion of the Pl.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Sponsor Role
collaborator
University Hospitals Cleveland Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kurt Lu
Assistant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kurt Lu, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am J Clin Nutr. 2008 Jun;87(6):1738-42. doi: 10.1093/ajcn/87.6.1738.
Reference Type
BACKGROUND
Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010 May 12;303(18):1815-22. doi: 10.1001/jama.2010.594.
Reference Type
BACKGROUND
van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Boer H. Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol. 2010 Apr;162(4):805-11. doi: 10.1530/EJE-09-0932. Epub 2010 Feb 5.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
06-13-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults
NCT01924910
COMPLETED
PHASE4
Pharmacokinetics of Calcifediol and Cholecalciferol
NCT02333682
COMPLETED
NA
Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease
NCT00511225
COMPLETED
NA
Efficacy of Daily Vitamin D3 Supplementation in Normal Weight Adolescents
NCT01058720
COMPLETED
PHASE4
The Influence of Vitamin D on Mineral Metabolism, Blood Pressure and Pulse Wave Analysis in Healthy Individuals
NCT00952562
COMPLETED
NA
Dietary Supplementation With 25-hydroxyvitamin D3 in Older Adults
NCT01398202
COMPLETED
NA
Supplementation With Cholecalciferol in Dialysis Patients
NCT01974245
COMPLETED
PHASE2
Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3
NCT00732758
COMPLETED
PHASE1
Effect of a Single Colecalciferol Dose on Insulin Resistance
NCT01075022
UNKNOWN
NA
To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans
NCT02802449
COMPLETED
NA
Cholecalciferol Supplementation for Sepsis in the ICU
NCT01896544
COMPLETED
PHASE3
Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial
NCT02452762
COMPLETED
PHASE2
A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients
NCT01650883
COMPLETED
NA
The Effect of Weight on Vitamin D Dose Response
NCT01013584
COMPLETED
NA
Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period
NCT02092701
COMPLETED
NA
Effect of Vitamin D Treatment on Fatigue
NCT02022475
COMPLETED
PHASE3
Vitamin D, Blood Pressure, Lipids, Infection and Depression
NCT00960232
COMPLETED
PHASE3
Vitamin D Needs of Early Adolescent Children
NCT00931580
COMPLETED
NA
Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents
NCT02414529
COMPLETED
NA
Vitamin D Levels Following Topical Application of Vitamin D Ointment
NCT02676674
COMPLETED
PHASE1
Vitamin D Administration in the Nursing Home
NCT00204919
COMPLETED
NA
Dosage Calculation for Vitamin D Treatment
NCT02186106
COMPLETED
PHASE4
Supplementation of Vitamin D in Patients With Type 2 Diabetes and Hypertension
NCT02204527
TERMINATED
NA
Improving the Understanding of the Response to Vitamin D Supplementation
NCT01465178
COMPLETED
PHASE3